文献速递炎症性肠病

溃疡性结肠炎回肠储袋肛管吻合术后的自然史:美国基于人群的队列研究

The Natural History After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: A Population-Based Cohort Study From the United States.
PubMed 文献 · Am J Gastroenterol · 2024-06-18

基于TriNetX电子健康记录网络的回顾性队列研究,纳入1331例因溃疡性结肠炎行结肠切除加回肠储袋肛管吻合术的患者,储袋炎发生率从术后第1年58%升至10年72%,储袋克罗恩样病10年内增至10.3%,储袋失败增至4.1%,先进治疗使用率10年达峰值14.4%。

要点

  • 储袋炎发生率从术后第1年58%升至10年72%。
  • 储袋克罗恩样病10年内增至10.3%,储袋失败增至4.1%。
  • 先进治疗使用率10年达峰值14.4%。

核心结论

  • 当前时代储袋炎症性疾病发生率仍高,14%的患者在回肠储袋肛管吻合术后需要使用先进治疗。

研究设计与样本

  • 在TriNetX电子健康记录研究网络进行的回顾性队列研究,纳入1331例因溃疡性结肠炎行结肠切除加回肠储袋肛管吻合术的患者。

主要发现

  • 储袋炎发生率从回肠储袋肛管吻合术后第1年58%升至术后10年72%。
  • 倾向评分匹配后,尼古丁依赖(aHR 1.61,95%CI 1.19-2.18)、抗肿瘤坏死因子治疗(aHR 1.33,95%CI 1.13-1.56)和结肠切除前维得利珠单抗治疗(aHR 1.44,95%CI 1.06-1.96)与回肠储袋肛管吻合术后前5年储袋炎风险增加相关。
  • 储袋克罗恩样病发生率在回肠储袋肛管吻合术后10年内增至10.3%,储袋失败增至4.1%。
  • 先进治疗使用率在回肠储袋肛管吻合术后10年达峰值14.4%。

关键数值与推荐

  • 储袋炎发生率:术后第1年58%,术后10年72%。
  • 储袋克罗恩样病发生率:术后10年内10.3%。
  • 储袋失败发生率:术后10年内4.1%。
  • 先进治疗使用率:术后10年峰值14.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There are limited data regarding the natural history after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). The principal objectives of this study were to identify 4 key outcomes in the natural history after IPAA within 1, 3, 5, and 10 years: the incidence of pouchitis, Crohn's-like disease of the pouch, use of advanced therapies after IPAA, and pouch failure requiring excision in a network of electronic health records. METHODS: We performed a retrospective cohort study in TriNetX, a research network of electronic health records. In addition to evaluating incidence rates, we also sought to identify factors associated with pouchitis and advanced therapy use within 5 years of IPAA after 1:1 propensity score matching, expressed as adjusted hazard ratios (aHRs). RESULTS: Among 1,331 patients who underwent colectomy with IPAA for UC, the incidence of pouchitis increased from 58% in the first year after IPAA to 72% at 10 years after IPAA. After propensity score matching, nicotine dependence (aHR 1.61, 95% confidence interval [CI] 1.19-2.18), antitumor necrosis factor therapy (aHR 1.33, 95% CI 1.13-1.56), and vedolizumab prior to colectomy (aHR 1.44, 95% CI 1.06-1.96) were associated with an increased risk of pouchitis in the first 5 years after IPAA. The incidence of Crohn's-like disease of the pouch increased to 10.3% within 10 years of IPAA while pouch failure increased to 4.1%. The incidence of advanced therapy use peaked at 14.4% at 10 years after IPAA. DISCUSSION: The incidence of inflammatory conditions of the pouch remains high in the current era, with 14% of patients requiring advanced therapies after IPAA.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Barnes EL, Desai A, Hashash JG, et al. The Natural History After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: A Population-Based Cohort Study From the United States. Am J Gastroenterol. 2024. PMID: 38888231. doi:10.14309/ajg.0000000000002891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。